OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Yong-Ping Lu, Zeyu Zhang, Hongwei Wu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure
Milton Packer
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 2, pp. 371-381
Open Access | Times Cited: 24

Mitochondrial metabolic reprogramming in diabetic kidney disease
Xiaoting Fan, Meilin Yang, Yating Lang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 18

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ameliorate renal ischemia-reperfusion injury (IRI) by modulating autophagic processes
Mengmeng Liu, Yuanqing Yao, Fangyan Tan, et al.
Translational research (2025) Vol. 277, pp. 27-38
Closed Access | Times Cited: 2

Kidney fibrosis: Emerging diagnostic and therapeutic strategies
Barbara M. Klinkhammer, Peter Boor
Molecular Aspects of Medicine (2023) Vol. 93, pp. 101206-101206
Closed Access | Times Cited: 24

Potentials of Natural Antioxidants in Reducing Inflammation and Oxidative Stress in Chronic Kidney Disease
On Ying Angela Lee, Alex Ngai Nick Wong, Ching Yan Ho, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 751-751
Open Access | Times Cited: 12

Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns
Mingwei Shao, Duo Chen, Qingzhu Wang, et al.
Diabetologia (2024) Vol. 67, Iss. 4, pp. 738-754
Closed Access | Times Cited: 8

Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7

Abnormal tryptophan catabolism in diabetes mellitus and its complications: Opportunities and challenges
Jialiang Gao, Ting Yang, Bohan Song, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115395-115395
Open Access | Times Cited: 15

Reno-protective Effects of Empagliflozin in High Fat Diet Induced Obesity-Related Glomerulopathy by Regulation of Gut-Kidney Axis
Lei Lei, Ting Zhu, Tian-Jiao Cui, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 4, pp. C994-C1011
Open Access | Times Cited: 6

SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study
Zhijuan Wang, Jie Wei, Wenman Zhao, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Martina Belli, Lucy Barone, Alfonso Bellia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14598-14598
Open Access | Times Cited: 18

Leukocyte–endothelial interaction in CKD
Tamim Sarakpi, Armir Mesic, Thimoteus Speer
Clinical Kidney Journal (2023) Vol. 16, Iss. 11, pp. 1845-1860
Open Access | Times Cited: 10

Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors
Wenwen Guo, Han Li, Yixuan Li, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115025-115025
Open Access | Times Cited: 10

Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
Yifei Zhang, Yuxiang Liu, Wuxiao Yang
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access

Global research trends on the associations between chronic kidney disease and mitochondria: insights from the bibliometric analysis
Xinfang Tang, Anna Zhang, Xiaojuan Feng, et al.
International Urology and Nephrology (2025)
Closed Access

Mitochondrial Changes Induced by SGLT2i in Lymphocytes from Diabetic Kidney Transplant Recipients: A Pilot Study
Isabel Pérez-Flores, Andrea R. López‐Pastor, Ulises Gómez-Pinedo, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3351-3351
Open Access

Perturbed gut microbiota and serum metabolites are associated with progressive renal fibrosis
Run-Xi Wang, Hong-Bing Zhou, Jin Gao, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access

Kidney morphology in INSRR gene knockout mice under bicarbonate loading conditions
E. A. Gantsova, О. В. Серова, I. E. Deyev, et al.
Morphology (2025)
Closed Access

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
Hyung Ah Jo, Jong-Hyun Seo, Sunhwa Lee, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Julia Hoehlschen, Dominik Hofreither, Tamara Tomin, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7

Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes
Viktor Rotbain Curovic, Brede A Sørland, Tine W. Hansen, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 2, pp. e003973-e003973
Open Access | Times Cited: 2

Fasn involved in the nephrotoxicity induced by polystyrene nanoplastics and the intervention of melatonin through intestinal microbiota-mediated lipid metabolism disorder
Huiwen Kang, Danyang Huang, Jiaru Jing, et al.
Nano Research (2024) Vol. 17, Iss. 8, pp. 7365-7375
Closed Access | Times Cited: 2

Page 1 - Next Page

Scroll to top